Genome Medicine (Feb 2021)

Noninvasive prenatal testing of α-thalassemia and β-thalassemia through population-based parental haplotyping

  • Chao Chen,
  • Ru Li,
  • Jun Sun,
  • Yaping Zhu,
  • Lu Jiang,
  • Jian Li,
  • Fang Fu,
  • Junhui Wan,
  • Fengyu Guo,
  • Xiaoying An,
  • Yaoshen Wang,
  • Linlin Fan,
  • Yan Sun,
  • Xiaosen Guo,
  • Sumin Zhao,
  • Wanyang Wang,
  • Fanwei Zeng,
  • Yun Yang,
  • Peixiang Ni,
  • Yi Ding,
  • Bixia Xiang,
  • Zhiyu Peng,
  • Can Liao

DOI
https://doi.org/10.1186/s13073-021-00836-8
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Background Noninvasive prenatal testing (NIPT) of recessive monogenic diseases depends heavily on knowing the correct parental haplotypes. However, the currently used family-based haplotyping method requires pedigrees, and molecular haplotyping is highly challenging due to its high cost, long turnaround time, and complexity. Here, we proposed a new two-step approach, population-based haplotyping-NIPT (PBH-NIPT), using α-thalassemia and β-thalassemia as prototypes. Methods First, we deduced parental haplotypes with Beagle 4.0 with training on a large retrospective carrier screening dataset (4356 thalassemia carrier screening-positive cases). Second, we inferred fetal haplotypes using a parental haplotype-assisted hidden Markov model (HMM) and the Viterbi algorithm. Results With this approach, we enrolled 59 couples at risk of having a fetus with thalassemia and successfully inferred 94.1% (111/118) of fetal alleles. We confirmed these alleles by invasive prenatal diagnosis, with 99.1% (110/111) accuracy (95% CI, 95.1–100%). Conclusions These results demonstrate that PBH-NIPT is a sensitive, fast, and inexpensive strategy for NIPT of thalassemia.

Keywords